scholarly journals Correction: Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
Author(s):  
Andrew R. Moore ◽  
Malcolm Boyce ◽  
Islay A. Steele ◽  
Fiona Campbell ◽  
Andrea Varro ◽  
...  
Keyword(s):  
Atrophic Gastritis ◽  
Receptor Antagonist ◽  
Neuroendocrine Tumours ◽  
Chronic Atrophic Gastritis ◽  
Gastrin Receptor ◽  
Tumour Biomarkers

The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours

2016 ◽  
Vol 28 (11) ◽  
pp. 1345-1352 ◽  
Author(s):  
Liv Sagatun ◽  
Patricia Mjønes ◽  
Constantin S. Jianu ◽  
Malcolm Boyce ◽  
Hege L. Waldum ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Neuroendocrine Tumours ◽  
Gastrin Receptor

57 Treatment of Gastric Carcinoids Type 1 With the Gastrin Receptor Antagonist YF476 Results in Regression of Tumours and Normalisation of Serum Chromogranin A

2012 ◽  
Vol 142 (5) ◽  
pp. S-15 ◽  
Author(s):  
Reidar Fossmark ◽  
Øystein Sørdal ◽  
Constantin S. Jianu ◽  
Gunnar Qvigstad ◽  
Malcolm J. Boyce ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Chromogranin A ◽  
Gastrin Receptor ◽  
Gastric Carcinoids

Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis

Endocrine ◽  
2009 ◽  
Vol 35 (3) ◽  
pp. 420-428 ◽  
Author(s):  
Núria Alonso ◽  
María Jesús Martínez-Arconada ◽  
María Luisa Granada ◽  
Berta Soldevila ◽  
Ana Cantón ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Atrophic Gastritis ◽  
Chronic Atrophic Gastritis ◽  
Diabetic Patients ◽  
Type 1 Diabetic Patients

scholarly journals Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids

2005 ◽  
Vol 152 (3) ◽  
pp. 443-448 ◽  
Author(s):  
M Peracchi ◽  
C Gebbia ◽  
G Basilisco ◽  
M Quatrini ◽  
C Tarantino ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Healthy Subjects ◽  
Chromogranin A ◽  
Neuroendocrine Tumours ◽  
Chronic Atrophic Gastritis ◽  
Cell Hyperplasia ◽  
Gastric Carcinoids ◽  
Ecl Cell ◽  
Design And Methods

Objective: In atrophic body gastritis (ABG) chronic hypergastrinaemia stimulates enterochromaffin-like (ECL) cell proliferation with development of cell hyperplasia, dysplasia and possibly type-1 gastric carcinoids. As circulating chromogranin A (CgA) levels are a marker of neuroendocrine tumours, we evaluated the clinical usefulness of CgA assay in ABG patients to detect those with carcinoids. Design and methods: Plasma CgA levels were measured using a commercial ELISA in 45 healthy volunteers, nine patients with type-1 gastric carcinoids and 43 consecutive ABG patients (21 without and 22 with ECL cell hyperplasia/dysplasia). Results: CgA levels were significantly higher in ABG patients with and without gastric carcinoids than in healthy subjects (P < 0.001). The highest values occurred in patients with carcinoids (median (interquartile range): 58.1 (44.5–65.3) U/l) and with ECL cell hyperplasia/dysplasia (35.5 (31.8–48.65) U/l) but there were no significant differences in CgA among the various subgroups of ABG patients classified according to ECL cell status. Nevertheless, in ABG patients without carcinoids CgA values correlated with the presence and severity of ECL cell lesions (r s = 0.428, P < 0.01). The sensitivity and specificity of the CgA assay in identifying patients with carcinoids were 100 and 23% respectively. Conclusions: CgA plasma levels reflect the histological degree of ECL cell lesions in patients with ABG but the assay specificity is too low to detect among these patients those with gastric carcinoids.

Sign in / Sign up

Export Citation Format

Share Document